Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FB101
- Development stage
- Unknown
- Lead developer
- Freya Biosciences
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Vaginal
01
Overview
FB101 is an investigational vaginal microbial immunotherapeutic developed by Freya Biosciences as a vaginal microbiome transplant (VMT). It is designed to treat asymptomatic vaginal dysbiosis by restoring a healthy, Lactobacillus-dominated environment. The product contains a consortium of Lactobacillus species, including L. crispatus, L. gasseri, and L. jensenii, which are intended to engraft in the vaginal tract and displace dysbiotic bacteria. By shifting the microbiome, FB101 aims to reduce inflammatory markers and improve reproductive health outcomes, particularly for women undergoing in vitro fertilization (IVF). It is also being explored for the prevention of preterm birth and the treatment of endometriosis-related infertility.
- Other names
- vaginal microbial immunotherapeuticvaginal microbiome transplantVMT
Beyond the preview
Go deeper on FB101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FB101.